Clinical Trials · NCT01240941

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Name: Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Withdrawn
Sponsor: Vanderbilt-Ingram Cancer Center
Enrollment: 0
Start date: Feb 2011
Locations: See registry
Primary endpoint: Efficacy endpoint: Antitumor activity of MK-2206 when combined with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor positive metastatic breast cancer, measured by clinical benefit rate.

View Gonadorelin compound reference